Literature DB >> 12373042

Cardiac structural involvement in mucopolysaccharidoses.

Donato Rigante1, Giuseppe Segni.   

Abstract

Mucopolysaccharidoses (MPS) are lysosomal storage disorders due to impaired glycosaminoglycan degradation. Cardiac involvement is present in most patients with MPS although its clinical impact is still undetermined. Cardiovascular abnormalities were evaluated in 39 patients with MPS aged 4-22 years. Valvular lesions and different forms of cardiac involvement were detected. The most common lesion was thickening of the mitral valve with regurgitation or stenosis, regardless of the MPS type. Mitral valve thickening was observed in 23 patients, aortic valve thickening in 11 patients and congestive heart failure in only 1 patient with MPS III. The most severe changes were registered for MPS types I and II. Complete cardiological investigation should be routinely warranted in every patient inflicted with MPS. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 12373042     DOI: 10.1159/000064674

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  11 in total

1.  Cardiovascular Abnormalities in Egyptian Children with Mucopolysaccharidoses.

Authors:  Laila Selim; Nehal Abdelhamid; Emad Salama; Amera Elbadawy; Iman Gamaleldin; Mohamed Abdelmoneim; Abeer Selim
Journal:  J Clin Diagn Res       Date:  2016-11-01

Review 2.  Radiological and clinical characterization of the lysosomal storage disorders: non-lipid disorders.

Authors:  E I Parker; M Xing; A Moreno-De-Luca; E Harmouche; M R Terk
Journal:  Br J Radiol       Date:  2013-11-14       Impact factor: 3.039

3.  Urgent resection of a giant left atrial appendage aneurysm and mitral valve replacement in a complex case of Hurler-Scheie syndrome.

Authors:  Andrew Brazier; Ragheb Hasan; Petra Jenkins; Andreas Hoschtitzky
Journal:  BMJ Case Rep       Date:  2015-11-05

4.  Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI.

Authors:  Marion M M G Brands; Ingrid M Frohn-Mulder; Marloes L C Hagemans; Wim C J Hop; Esmee Oussoren; Wim A Helbing; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2012-01-26       Impact factor: 4.982

Review 5.  Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management.

Authors:  Elizabeth A Braunlin; Paul R Harmatz; Maurizio Scarpa; Beatriz Furlanetto; Christoph Kampmann; James P Loehr; Katherine P Ponder; William C Roberts; Howard M Rosenfeld; Roberto Giugliani
Journal:  J Inherit Metab Dis       Date:  2011-07-09       Impact factor: 4.982

Review 6.  Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.

Authors:  J Edmond Wraith; Maurizio Scarpa; Michael Beck; Olaf A Bodamer; Linda De Meirleir; Nathalie Guffon; Allan Meldgaard Lund; Gunilla Malm; Ans T Van der Ploeg; Jiri Zeman
Journal:  Eur J Pediatr       Date:  2007-11-23       Impact factor: 3.183

7.  The Murine Model of Mucopolysaccharidosis IIIB Develops Cardiopathies over Time Leading to Heart Failure.

Authors:  Gabriele Giacomo Schiattarella; Giuliana Cerulo; Valeria De Pasquale; Pasquale Cocchiaro; Orlando Paciello; Luigi Avallone; Maria Paola Belfiore; Francesca Iacobellis; Daniele Di Napoli; Fabio Magliulo; Cinzia Perrino; Bruno Trimarco; Giovanni Esposito; Paola Di Natale; Luigi Michele Pavone
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

8.  Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I.

Authors:  O I I Soliman; R G M Timmermans; A Nemes; W B Vletter; J H P Wilson; F J ten Cate; M L Geleijnse
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

9.  EGFR activation triggers cellular hypertrophy and lysosomal disease in NAGLU-depleted cardiomyoblasts, mimicking the hallmarks of mucopolysaccharidosis IIIB.

Authors:  Valeria De Pasquale; Antonio Pezone; Patrizia Sarogni; Alfonso Tramontano; Gabriele Giacomo Schiattarella; Vittorio Enrico Avvedimento; Simona Paladino; Luigi Michele Pavone
Journal:  Cell Death Dis       Date:  2018-01-18       Impact factor: 8.469

10.  Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).

Authors:  Molly Stapleton; Francyne Kubaski; Robert W Mason; Hiromasa Yabe; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2017-03-08       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.